ACIU
Companies
NASDAQ
Acimmune SA
Health Care
$1.92
-$0.74 (-27.22%)
Price Chart
Overview
About ACIU
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Market Cap
$471.7M
Volume
417.6K
Avg. Volume
380.4K
P/E Ratio
-6.44
Dividend Yield
0.00%
Employees
165.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.04
Moderate Correlation
Volatility
High (0.65)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ACIU shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$471.7M
Volume417.6K
P/E Ratio-6.44
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 13, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025